Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stacey McKelvey

Gastroenterology Barrington, IL Medical Doctor

NPI 1164472312 CMS profile 143275

200 Fox Glen Ct, Barrington, IL 60010

Open in the dashboard

General payments

$16,745

877 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stacey McKelvey of Barrington, IL is reported in the CMS Open Payments database as having received $16,745 across 877 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,381 155
2024 General $3,358 168
2023 General $3,224 162
2022 General $2,339 120
2021 General $2,126 115
2020 General $666 41
2019 General $1,651 116

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stacey McKelvey
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Stacey McKelvey were reported at $3,381. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Stacey McKelvey Gastroenterology median Middle half National median
2019 $1,651 $417 $126–$1,100 $163
2020 $666 $224 $74–$624 $114
2021 $2,126 $352 $106–$1,054 $132
2022 $2,339 $448 $129–$1,270 $149
2023 $3,224 $533 $150–$1,390 $160
2024 $3,358 $605 $160–$1,606 $164
2025 $3,381 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,851 176 payments
  2. Janssen Biotech, Inc. $2,364 134 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,899 105 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,706 105 payments
  5. Pfizer Inc. $815 65 payments
  6. Gilead Sciences, Inc. $670 34 payments
  7. QOL Medical, LLC $669 37 payments
  8. Nestle HealthCare Nutrition Inc. $569 30 payments
  9. Ardelyx, Inc. $498 20 payments
  10. Madrigal Pharmaceuticals $442 9 payments
  11. Other $3,262 162 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,610 866 payments
  2. Education $135 11 payments
Products named General payments · program years 2019–2025
  1. STELARA $1,883 110 payments
  2. XIFAXAN $1,340 82 payments
  3. ENTYVIO $1,174 58 payments
  4. RINVOQ $1,097 42 payments
  5. LINZESS $836 38 payments
  6. CREON $798 41 payments
  7. SIMPONI ARIA $731 41 payments
  8. REMICADE $731 41 payments
  9. SIMPONI $731 41 payments
  10. XELJANZ $658 53 payments
  11. Other $10,343 530 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,130

Median for Gastroenterology: 569

Drug cost

$1,335,200

Median for Gastroenterology: $104,976

Branded share of claims

35.6%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 24 $661,190
Humira(Cf) Pen Adalimumab Brand 29 $232,988
Zenpep Lipase/Protease/Amylase Brand 22 $102,418
Rinvoq Upadacitinib Brand 13 $101,285
Creon Lipase/Protease/Amylase Brand 20 $59,785
Vemlidy Tenofovir Alafenamide Brand 21 $44,030
Xifaxan Rifaximin Brand 14 $31,503
Linzess Linaclotide Brand 26 $26,218
Pentasa Mesalamine Brand 11 $24,716
Mesalamine Er Mesalamine Brand 20 $11,242

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$81,772

Medicare's payments for the services billed

Medicare patients

385

Average age 73

Services billed

908

268 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 55%
Depression 32%
Diabetes 31%
Ischemic heart disease 31%
Chronic kidney disease 30%
Heart failure 22%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
$351 24 —
TREMFYA
$254 — —
XIFAXAN
$252 14 —
ENTYVIO
$226 — —
IBSRELA
$215 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

877 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record